Skip to Content
Investing Specialists

10 Conviction Buy Ideas from Our Top Managers

The holdings of a majority of our Ultimate Stock-Pickers yield 10 5-Star stocks.

Mentioned: , , , , , , , , ,

By Greggory Warren, CFA | Senior Stock Analyst

With over two-thirds of our Ultimate Stock-Pickers having reported their third-quarter holdings, we've been able to glean some of the higher conviction purchases made by our top managers during the most recent period. Much as we had noted last quarter there was a fair amount of buying going on in the health care sector, with at least 19 different securities purchased by our Ultimate Stock-Pickers during the quarter. It wasn't too surprising to see large-cap health care names like  Pfizer (PFE) and  Johnson & Johnson (JNJ) pop up as conviction purchases. However, given the impact that near-term concerns over a government-sponsored health-care plan have had on the stock prices of firms in this sector, it was interesting to see a couple of non-traditional names see new money purchases as well, namely  DENTSPLY International (XRAY) and  Patterson Companies (PDCO), both of which are focused on dental products.

Our Ultimate Stock-Pickers were also putting money to work in the industrial materials sector, which is another unique Morningstar sector designation that encompasses everything from producers of farm equipment and agricultural products (like  Deere (DE) and  Monsanto (MON)), to aerospace firms (such as  Boeing (BA)) and waste haulers (like  Waste Management (WM)). Our top managers bought 22 different names in the sector, with  Republic Services (RSG) being the one name that was bought with the most conviction. As you may recall from one of our more recent articles,  Oak Value Fund (OAKVX) made a significant new money purchase of Republic Services, the nation's second-largest non-hazardous solid waste company behind Waste Management, during the third quarter (contributing greatly to its designation as a high conviction purchase during the period).

The Morningstar Ultimate Stock-Pickers Team does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.